Trade Names:Maxair Autohaler- Aerosol 0.2 mg/actuation
Produces bronchodilation by relaxing bronchial smooth muscle through beta-2 receptor stimulation.
Rapidly absorbed following aerosol administration.
51% of the dose is excreted in the urine plus its sulfate conjugate. T ½ and plasma is approximately 2 h (oral).
5 min (inhalation).
5 h (inhalation).
Prevention and treatment of reversible bronchospasm associated with asthma or other obstructive pulmonary diseases.
Hypersensitivity to drug components; cardiac arrhythmias associated with tachycardia.
Inhalation 1 to 2 inhalations every 4 to 6 h; not to exceed 12 inhalations/day.
Store at room temperature.
May increase the effects of pirbuterol.
None well documented.
Palpitations; tachycardia; BP changes; chest tightness/pain/discomfort; angina; arrhythmias/skipped beats.
Tremor; anxiety; confusion; fatigue; dizziness; nervousness; headache; weakness; hyperactivity/hyperkinesia/excitement; insomnia.
Dry nose; throat irritation.
GI distress; dry mouth; diarrhea; nausea/vomiting.
Cough; throat irritation.
Flushing; anorexia/appetite loss; unusual/bad taste; taste/smell change.
Category C .
Safety and efficacy in children 12 yr of age and younger not established.
Lower doses may be required.
May inhibit uterine contractions and delay preterm labor.
Toxic symptoms in patients with CV disorders may occur.
CNS stimulation may occur; use cautiously in patients with history of seizure or hyperthyroidism.
Dosage adjustment of insulin or oral hypoglycemic agent may be required.
Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use.
Decreases in potassium levels have occurred.
If previously effective dose fails to provide relief therapy may need to be reassessed.
Tremor, palpitations, tachycardia, elevated blood pressure, anginal pain, hypokalemia, seizures.
Copyright © 2009 Wolters Kluwer Health.